Canterbury DHB

Context

Management of Relapse or Refractory Patients

Patients who relapse from AML17, can be entered into the treatment arm for high risk patients in AML19.

Key Questions for relapse/refractory patients:

If remission was obtained:

What does the patient want?

These considerations will dictate management and vary from patient to patient.

Check to see if there is a relapse/refractory trial to offer the patient. See the Clinical Trials page on the Intranet or phone the Clinical Trials Co-ordinator (ext: 80377).

In This Section

Idarubicin / Cytarabine Protocol

About this Canterbury DHB document (4291):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4291